ABHD12
ENSG00000100997
Target class
Enzyme
Chromosome
20
- ClinGen gene-disease validity
- Definitive
- Chemical probe available
- Yes
- Target name
- ABHD12
- Gene name
- Abhydrolase domain containing 12, lysophospholipase
- Gene symbol
- ABHD12
- Previous gene symbols
- C20orf22
- Protein name
- Lysophosphatidylserine lipase ABHD12 (EC 3.1.-.-) (2-arachidonoylglycerol hydrolase ABHD12) (Abhydrolase domain-containing protein 12) (hABHD12) (Monoacylglycerol lipase ABHD12) (EC 3.1.1.23) (Oxidized phosphatidylserine lipase ABHD12) (EC 3.1.-.-)
- DKFZP434P106
- dJ965G21.2
- BEM46L2
- ABHD12A
- Gene biotype
- Protein coding
- Gene family
- Abhydrolase domain containing|2-arachidonoylglycerol hydrolases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 109.89
- Tissue specificity (Gini)
- 0.273
- Tissue specificity (tau)
- 0.62
- KEGG gene identifiers
- hsa:26090
- Reactome pathways
- R-HSA-426048
- Protein interaction confidence
- 0.821
- Protein interaction partners
- 8
- End position
- 25390866
- Start position
- 25294742
- Chromosome
- 20
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Single-pass membrane protein .
Publication evidence
- PubMed 30237167
- Tissue specificity (tau)
- 0.620401
- Expression inequality (Gini)
- 0.272939
Expression in transcripts per million
- Thyroid
- 109.89
- Brain - Spinal cord (cervical c-1)
- 105.87
- Nerve - Tibial
- 92.88
- Brain - Frontal Cortex (BA9)
- 82.39
- Brain - Cerebellar Hemisphere
- 78.43
Expression in transcripts per million
- Thyroid109.89
- Brain - Spinal cord (cervical c-1)105.87
- Nerve - Tibial92.88
- Brain - Frontal Cortex (BA9)82.39
- Brain - Cerebellar Hemisphere78.43
- Brain - Cerebellum75.41
- Brain - Cortex74.73
- Brain - Nucleus accumbens (basal ganglia)65.89
- Brain - Hippocampus62.78
- Brain - Anterior cingulate cortex (BA24)60.09
- Brain - Caudate (basal ganglia)57.75
- Brain - Hypothalamus56.65
- Brain - Substantia nigra54.51
- Skin - Sun Exposed (Lower leg)52.25
- Brain - Putamen (basal ganglia)51.78
- Pituitary50.66
- Skin - Not Sun Exposed (Suprapubic)46.84
- Cells - Cultured fibroblasts45.09
- Cervix - Ectocervix43.38
- Brain - Amygdala42.52
- Prostate41.47
- Vagina40.18
- Esophagus - Mucosa39.9
- Ovary39.4
- Lung38.53
And 29 more, listed on the interactive page.
- GO:0006660
- GO:0009395
- GO:0019369
- GO:0046464
- GO:0046475
- GO:0052651
- GO:0005789
- GO:0005886
- GO:0004620
- GO:0004622
- GO:0047372
- GO:0120560
Related records
Trials (58)
- A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
- A Trial With EMP16 in Preparation for Late Phase Studies
- Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
- Comparison of MAG and Fish Oil Efficacy
- Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
- Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity
- Effect of Orlistat in Body Composition
- Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial
- Effectiveness of Brief Counseling for Weight Management
- Efficacy and Safety of ATL-962 in Obese Diabetics
- Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease